Cargando…

Assessing Prognostic and Predictive Biomarkers of Regorafenib Response in Patients with Advanced Soft Tissue Sarcoma: REGOSARC Study

SIMPLE SUMMARY: In a double-blind, placebo-controlled, randomized phase 2 trial, Regorafenib provided a clinical benefit to patients with advanced and anthracycline-pretreated soft tissue sarcoma. However, extensive mutational analysis of tumor genes could not identify predictive markers of regorafe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brodowicz, Thomas, Liegl-Atzwanger, Bernadette, Penel, Nicolas, Mir, Olivier, Blay, Jean-Yves, Kashofer, Karl, Le Cesne, Axel, Decoupigny, Emilie, Wallet, Jennifer, Hamacher, Rainer, Le Deley, Marie-Cecile
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7763753/ https://www.ncbi.nlm.nih.gov/pubmed/33322802 http://dx.doi.org/10.3390/cancers12123746

Ejemplares similares

REGOSARC: Regorafenib versus placebo in doxorubicin‐refractory soft‐tissue sarcoma—A quality‐adjusted time without symptoms of progression or toxicity analysis
por: Berry, Vincent, et al.
Publicado: (2017)

Study protocol of REGOSARC trial: activity and safety of regorafenib in advanced soft tissue sarcoma: a multinational, randomized, placebo-controlled, phase II trial
por: Brodowicz, Thomas, et al.
Publicado: (2015)

Diagnosis and treatment of soft-tissue sarcomas of the extremities and trunk
por: Smolle, Maria Anna, et al.
Publicado: (2017)

Detection of GNAS mutations in intramuscular / cellular myxomas as diagnostic tool in the classification of myxoid soft tissue tumors
por: Sunitsch, Sandra, et al.
Publicado: (2018)

MicroRNAs in Different Histologies of Soft Tissue Sarcoma: A Comprehensive Review
por: Smolle, Maria Anna, et al.
Publicado: (2017)

Expression and prognostic significance of PDGF ligands and receptors across soft tissue sarcomas
por: Brahmi, M., et al.
Publicado: (2021)

KIT mutation in a naïve succinate dehydrogenase‐deficient gastric GIST
por: Brcic, Iva, et al.
Publicado: (2019)

Immunologic constant of rejection signature is prognostic in soft-tissue sarcoma and refines the CINSARC signature
por: Bertucci, Francois, et al.
Publicado: (2022)

PARP1 expression in soft tissue sarcomas is a poor‐prognosis factor and a new potential therapeutic target
por: Bertucci, François, et al.
Publicado: (2019)

Pharmacogenetic Study of Trabectedin-Induced Severe Hepatotoxicity in Patients with Advanced Soft Tissue Sarcoma
por: Maillard, Maud, et al.
Publicado: (2020)

Pre-Treatment Anemia Is a Poor Prognostic Factor in Soft Tissue Sarcoma Patients
por: Szkandera, Joanna, et al.
Publicado: (2014)

The Prognostic Impact of Unplanned Excisions in a Cohort of 728 Soft Tissue Sarcoma Patients: A Multicentre Study
por: Smolle, Maria Anna, et al.
Publicado: (2017)

Once weekly paclitaxel associated with a fixed dose of oral metronomic cyclophosphamide: a dose-finding phase 1 trial
por: Pannier, Diane, et al.
Publicado: (2018)

Broadening the spectrum of NTRK rearranged mesenchymal tumors and usefulness of pan-TRK immunohistochemistry for identification of NTRK fusions
por: Brčić, Iva, et al.
Publicado: (2020)

Case Report: Epstein-Barr-Virus negative diffuse large B-cell lymphoma detected in a peri-prosthetic membrane
por: Sunitsch, Sandra, et al.
Publicado: (2016)

Pregnancy in Women with Metastatic Sarcomas
por: Yazigi, Alexandre, et al.
Publicado: (2020)

Clinical implementation of plasma cell-free circulating tumor DNA quantification by digital droplet PCR for the monitoring of Ewing sarcoma in children and adolescents
por: Seidel, Markus G., et al.
Publicado: (2022)

Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial
por: Lebellec, Loïc, et al.
Publicado: (2018)

CSPG4 expression in soft tissue sarcomas is associated with poor prognosis and low cytotoxic immune response
por: Boudin, Laurys, et al.
Publicado: (2022)

Establishment of a novel cellular model for myxofibrosarcoma heterogeneity
por: Lohberger, Birgit, et al.
Publicado: (2017)

Impact of allogeneic red blood cell transfusion on prognosis in soft tissue sarcoma patients. A single‐centre study
por: Smolle, Maria Anna, et al.
Publicado: (2022)

Circulating vascular endothelial growth factor (VEGF) as predictive factor of progression-free survival in patients with advanced chordoma receiving sorafenib: an analysis from a phase II trial of the french sarcoma group (GSF/GETO)
por: Lebellec, Loic, et al.
Publicado: (2016)

Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study
por: Savina, Marion, et al.
Publicado: (2017)

Prospective evaluation of intensity-modulated radiotherapy toxicity in extremity soft tissue sarcomas patients: A role for irradiated healthy soft tissue volume?
por: Bourdais, Rémi, et al.
Publicado: (2021)

Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses
por: Cesne, Axel Le, et al.
Publicado: (2019)

Molecular profiling of soft-tissue sarcomas with FoundationOne(®) Heme identifies potential targets for sarcoma therapy: a single-centre experience
por: Scheipl, Susanne, et al.
Publicado: (2021)

French Sarcoma Group proposals for management of sarcoma patients during the COVID-19 outbreak
por: Penel, N., et al.
Publicado: (2020)

Diabetes mellitus is independently associated with adverse clinical outcome in soft tissue sarcoma patients
por: Stelzl, Adrian, et al.
Publicado: (2020)

Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study
por: Sleijfer, S, et al.
Publicado: (2012)

The cost-saving effect of centralized histological reviews with soft tissue and visceral sarcomas, GIST, and desmoid tumors: The experiences of the pathologists of the French Sarcoma Group
por: Perrier, Lionel, et al.
Publicado: (2018)

Elevated preoperative neutrophil/lymphocyte ratio is associated with poor prognosis in soft-tissue sarcoma patients
por: Szkandera, J, et al.
Publicado: (2013)

Incidence, treatment and outcome of abdominal metastases in extremity soft tissue sarcoma: Results from a multi‐centre study
por: Smolle, Maria A., et al.
Publicado: (2020)

Validation of the prognostic relevance of plasma C-reactive protein levels in soft-tissue sarcoma patients
por: Szkandera, J, et al.
Publicado: (2013)

Development of a disease-specific graded prognostic assessment index for the management of sarcoma patients with brain metastases (Sarcoma-GPA)
por: Patrikidou, Anna, et al.
Publicado: (2020)

Aldehyde Dehydrogenase 1, a Potential Marker for Cancer Stem Cells in Human Sarcoma
por: Lohberger, Birgit, et al.
Publicado: (2012)

Leiomyosarcoma of Bone: A Case Report
por: Frings, Andreas, et al.
Publicado: (2011)

Update on Molecular Genetics of Gastrointestinal Stromal Tumors
por: Brčić, Iva, et al.
Publicado: (2021)

Early phase trials in soft-tissue sarcomas: clinical benefit of inclusion in early lines of treatment, molecular screening, and histology-driven trials
por: Nassif, E.F., et al.
Publicado: (2022)

Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first‐line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer‐Soft Tissue and Bone Sarcoma Group (EORTC‐STBSG)
por: Lindner, Lars H., et al.
Publicado: (2018)

Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group
por: Khalifa, J., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ljqvl57tht8i0tg7sqjm3b415n